CLINICAL EXPERIENCE WITH A NEW PHENOTHIAZINE (PIPERACETAZINE)
Abstract
Piperacetazine, a new phenothiazine derivative of the piperidine series, was clinically evaluated in 75 recently admitted hospitalized psychiatric patients. It over-all effectiveness in the treatment of the acute psychiatric disorders studies appeared comparable to that of other commonly used phenothiazine derivatives. The incidence of extrapyramidal reactions was low.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
